Free tool
FAERS Monitor: Divigel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022038 or its brand name (Divigel, Estradiol). Reports on generic versions are filed under their own applications.
Reports
47,535
Serious
22,781
48% of reports
Hospitalization
7,317
Death reported
925
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,941
- headache2,924
- fatigue2,903
- nausea2,901
- off label use2,436
- pain2,096
- diarrhoea1,967
- dizziness1,746
- breast cancer female1,709
- arthralgia1,656
- pruritus1,576
- rash1,553
- dyspnoea1,544
- product adhesion issue1,539
- insomnia1,376
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 525 |
| 2005 | 572 |
| 2006 | 402 |
| 2007 | 1,461 |
| 2008 | 430 |
| 2009 | 600 |
| 2010 | 959 |
| 2011 | 851 |
| 2012 | 1,153 |
| 2013 | 923 |
| 2014 | 1,119 |
| 2015 | 1,927 |
| 2016 | 2,370 |
| 2017 | 2,169 |
| 2018 | 2,525 |
| 2019 | 2,933 |
| 2020 | 2,950 |
| 2021 | 2,889 |
| 2022 | 3,132 |
| 2023 | 3,622 |
| 2024 | 3,717 |
| 2025 | 5,267 |
| 2026 | 5,038 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,006,624 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,709 | 30.2 | 28.8 | 45,154 |
| product adhesion issueSignal | 1,539 | 19.9 | 18.9 | 26,420 |
| insomniaSignal | 1,376 | 2.3 | 2.2 | 1,009 |
| headacheSignal | 2,924 | 2.1 | 2.0 | 1,655 |
| pruritus | 1,576 | 1.8 | 1.7 | 587 |
| arthralgia | 1,656 | 1.8 | 1.7 | 558 |
| fatigue | 2,903 | 1.7 | 1.6 | 773 |
| nausea | 2,901 | 1.6 | 1.6 | 720 |
| rash | 1,553 | 1.6 | 1.5 | 334 |
| dizziness | 1,746 | 1.6 | 1.5 | 348 |
| pain | 2,096 | 1.5 | 1.4 | 372 |
| diarrhoea | 1,967 | 1.3 | 1.3 | 183 |
| drug ineffective | 3,941 | 1.3 | 1.3 | 332 |
| off label use | 2,436 | 1.2 | 1.2 | 110 |
| dyspnoea | 1,544 | 1.2 | 1.1 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.